Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
"We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about
van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG et al (2021) Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial
Combining both drugs simultaneously has no published evidence base, redundant receptor targets, additive adverse-event risk, and no guideline support
Coverage policies vary widely: a KFF 2025 employer survey found 43% of firms with 5,000+ workers now cover GLP-1 weight-loss drugs (up from 28% in 2024) ( [6] ), yet many patient advocacy reports and journalists note patients cutting doses or resorting to unapproved sources due to cost ( [4] ) ( [7] )
Anyone who wishes to take their well-being seriously can use it
Retrieved 15 November 2023
